MannKind Corporation
NASDAQ:MNKD · NASDAQ Global Market
-$0.02 today
Vol 11.62M · Avg 5.73M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $5.9M -78.7% | $27.6M +331.1% | -$11.9M +86.3% | -$87.4M -8.0% | -$80.9M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $12.3M +35.9% | $9.0M +55.8% | $5.8M -7.7% | $6.3M +14.9% | $5.5M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$5.0M | $0 | $0 | $0 -100.0% | $12.6M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $24.2M +13.3% | $21.4M +21.0% | $17.6M | $0 -100.0% | $12.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$86.3M -136.7% | -$36.5M -349.4% | $14.6M +160.8% | -$24.1M -35.7% | -$17.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$4.8M -279.6% | $2.7M +13.1% | $2.3M +119.9% | -$11.8M -1421.5% | -$776.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $10.4M +425.3% | -$3.2M -169.9% | $4.6M +180.7% | -$5.7M -38.9% | -$4.1M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$16.7M -499.4% | -$2.8M -89.3% | -$1.5M -136.0% | $4.1M +198.1% | $1.4M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$75.3M -127.1% | -$33.1M -461.0% | $9.2M +186.0% | -$10.7M +25.1% | -$14.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $67.2M +220.2% | $21.0M +163.9% | $8.0M -67.5% | $24.5M +268.9% | $6.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $18.3M -57.1% | $42.5M +24.7% | $34.1M +142.2% | -$80.7M -30.8% | -$61.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$4.6M +52.9% | -$9.7M +77.2% | -$42.4M -459.2% | -$7.6M +33.8% | -$11.5M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$347.7M | $0 | $0 +100.0% | -$15.3M +72.6% | -$56.1M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$157.8M +42.4% | -$273.8M -246.2% | -$79.1M -1481.9% | -$5.0M +97.5% | -$199.1M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $221.7M +281.4% | $58.1M -51.2% | $119.2M | $0 -100.0% | $59.1M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$16.4M -112.7% | $128.7M +33592.9% | $382.0K -98.8% | $32.8M -41.5% | $56.1M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$304.8M -215.4% | -$96.6M -4761.6% | -$2.0M -140.8% | $4.9M +103.2% | -$151.5M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $325.0M +344.1% | -$133.2M -1842.4% | -$6.9M -530.1% | -$1.1M -100.4% | $281.1M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.0M +132.7% | -$6.1M -188.4% | $6.9M -69.5% | $22.6M +1096.0% | $1.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$11.9M -697.9% | $2.0M -98.5% | $136.6M +220383.9% | -$62.0K +99.5% | -$12.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $315.1M +329.6% | -$137.3M -200.5% | $136.6M +538.2% | $21.4M -92.1% | $270.3M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $28.6M +114.9% | -$191.4M -213.4% | $168.7M +410.0% | -$54.4M -195.4% | $57.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $13.7M -58.3% | $32.8M +493.2% | -$8.3M +90.5% | -$88.3M -20.7% | -$73.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.49B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.09B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.92B
Nuvation Bio Inc.
NYSE:NUVB
$1.86B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.67B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.65B
Immunocore Holdings plc
NASDAQ:IMCR
$1.45B
Biohaven Ltd.
NYSE:BHVN
$1.41B
Janux Therapeutics, Inc.
NASDAQ:JANX
$842.20M
SEC Filings
Recent regulatory filings
No filings found.
Does MNKD generate free cash flow?
MannKind Corporation (MNKD) generated $13.69M of free cash flow in fiscal 2025.
How much operating cash flow does MNKD produce?
Operating cash flow was $18.25M, before capital expenditures of $4.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.